Arcus Biosciences, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 383.00M | 112.00M | 117.00M | 258.00M | 247.00M | -4.3% | |
| Cost of Revenue | — | — | — | — | (10.00M) | — | |
Gross Profit | 383.00M | 112.00M | 117.00M | 258.00M | 237.00M | -8.1% | |
| Operating Expenses | |||||||
| Research & Development | (257.00M) | (288.00M) | (340.00M) | (448.00M) | (523.00M) | 16.7% | |
| Selling, General & Administrative | (72.00M) | (104.00M) | (117.00M) | (120.00M) | (110.00M) | -8.3% | |
| General & Administrative | (72.00M) | (104.00M) | (117.00M) | (120.00M) | (110.00M) | -8.3% | |
| Depreciation & Amortization | (4.00M) | (6.00M) | (8.00M) | (10.00M) | (10.00M) | 0.0% | |
Operating Income (EBIT) | 54.00M | -280.00M | -340.00M | -330.00M | -386.00M | 17.0% | |
| Non-Operating Items | |||||||
| Interest Income | 1.00M | 16.00M | 41.00M | 52.00M | 41.00M | -21.2% | |
| Interest Expense | — | (2.00M) | (2.00M) | (4.00M) | (8.00M) | 100.0% | |
| Other Income/Expenses (Net) | 1.00M | 14.00M | 39.00M | 47.00M | 33.00M | -29.8% | |
Income Before Tax | 55.00M | -266.00M | -301.00M | -283.00M | -353.00M | 24.7% | |
| Income Tax Expense | (2.00M) | (1.00M) | (6.00M) | (1.00M) | — | -100.0% | |
Net Income | 53.00M | -267.00M | -307.00M | -283.00M | -353.00M | 24.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $1 | $-4 | $-4 | $-3 | $-3 | 4.8% | |
| Weighted Avg Shares Outstanding | 69.35M | 72.00M | 74.00M | 90.10M | 107.40M | 19.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 73.97M | 72.00M | 74.00M | 90.10M | 107.40M | 19.2% | |
EBITDA | 59.00M | -258.00M | -291.00M | -269.00M | -335.00M | 24.5% |
Explore RCUS
RCUS in the Healthcare
Mid Cap